The Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review
Open Access
- 28 September 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (19) , 6877
Abstract
Diabetes and cardiovascular diseases (CVDs) are two strongly associated conditions that mutually influence each other. This review aims to follow the historical timeline of their association by highlighting the changing paradigm in CV risk management and treatment strategies in type 2 diabetes (T2D). While the discovery of insulin was a breakthrough in reducing life-threatening complications like diabetic ketoacidosis, patients with diabetes still faced a poor prognosis in terms of macrovascular outcomes, especially CVDs. Initial efforts in improving outcomes by tightly controlling glycemia proved insufficient, highlighting the complex relationship between the two diseases. After decades of focusing solely on glucose-lowering strategies, rosiglitazone, a promising new drug was developed, ultimately raising the flag about the potential higher risk of CV complications like myocardial infarction associated with its use. This turning point shifted the focus towards CV safety of novel glucose-lowering drugs, mandating for the development of cardiovascular outcome trials. Several drug classes, like sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), exceeded expectations by not only providing safety but also benefits in patients with T2D and CVDs and becoming the new standard of care in T2D management. The historical evidence linking T2D and CVDs has shaped regulatory requirements for cardiovascular outcome trials, guideline recommendations, and current therapeutic strategies. These insights highlight the importance of early interventions and a multidisciplinary approach to optimize patient outcomes.Keywords
Funding Information
- Doctoral School of Medicine and Pharmacy of “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania
This publication has 124 references indexed in Scilit:
- Epidemiology of metabolic syndromePflügers Archiv - European Journal of Physiology, 2025
- Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settingsDiabetologia, 2022
- Review of the veteran affairs diabetes trial: Lessons learnedReviews in Endocrine and Metabolic Disorders, 2020
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal RiskJAMA, 2019
- Impact of FDA Guidance for Developing Diabetes Drugs on Trial Design: From Policy to PracticeCurrent Cardiology Reports, 2011
- The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) StudyDiabetologia, 2010
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 1998
- UK prospective diabetes study (UKPDS)Diabetologia, 1991
- The Deadly QuartetArchives of internal medicine (1960), 1989